GSK plc (GSK, GSK.L) announced Tuesday new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating ...

Respiratory Virus Hospitalization Surveillance Network (RESP-NET) is made up of three networks that monitor COVID-19, ...

GSK: Some independent pharmacists said demand during the autumn vaccination season for respiratory syncytial virus shots has ...

Some groups of Alberta seniors will be able to get the RSV vaccine, for free, starting later this month.The Alberta ...

GSK (NYSE:GSK) announced Tuesday that Arexvy, a Phase 3 trial for its FDA-approved vaccine against Respiratory Syncytial ...

GSK has announced positive results from a phase III trial of its Arexvy RSV vaccine, showing that just one dose of the treatment could help protect older adults at risk of RSV disease over three ...

Arexvy is the world's first approved RSV vaccine and results showed that after a single dose, cumulative efficacy over three full RSV seasons was clinically meaningful.

All infants are to be offered a vaccine against the respiratory syncytial (RS) virus from next year to cut the number of ...

The BBC Morning Live GP - who is also on Strictly - has warned people that they need to do one thing to protect themselves - ...

GSK said data from a late-phase study showed that its respiratory syncytial virus vaccine, Arexvy, granted protection over three full RSV seasons.

GSK presents positive data for AREXVY, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV ...

Healgen Scientific LLC, a leading innovator in diagnostic solutions, announced the U.S. Food and Drug Administration (FDA) has granted De Novo marketing authorization for Healgen Rapid Check® COVID-19 ...